Impact of KIT D816 mutation on salvage therapy in relapsed acute myeloid leukemia with t(8;21) translocation
10.3760/cma.j.issn.0253-2727.2018.06.004
- VernacularTitle: KIT D816突变对伴t(8;21)复发急性髓系白血病预后的影响
- Author:
Benfa GONG
;
Yehui TAN
;
Aijun LIAO
;
Jian LI
;
Yueying MAO
;
Ning LU
;
Yi DING
;
Erlie JIANG
;
Tiejun GONG
;
Zhilin JIA
;
Yu SUN
;
Bingzong LI
;
Shuchuan LIU
;
Juan DU
;
Wenrong HUANG
;
Hui WEI
;
Jianxiang WANG
1
Author Information
1. Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, Tianjin Clinical Research Center for Blood Diseases, Tianjin 300020, China
- Publication Type:Journal Article
- Keywords:
Mutation;
Gene, KIT;
Leukemia, myeloid, acute;
Recurrence;
Prognosis
- From:
Chinese Journal of Hematology
2018;39(6):460-464
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To evaluate the impact of KIT D816 mutation on the salvage therapy in relapsed acute myeloid leukemia (AML) with t(8;21) translocation.
Method:The characteristics of the first relapsed AML with t(8;21) translocation from 10 hospitals were retrospectively collected, complete remission (CR2) rate after one course salvage chemotherapy and the relationship between KIT mutation and CR2 rate was analyzed.
Results:68 cases were enrolled in this study, and 30 cases (44.1%) achieved CR2. All patients received KIT mutation detection, and KIT D816 mutation was identified in 26 cases. The KIT D816 positive group had significantly lower CR2 compared with non-KIT D816 group (23.1% vs 57.1%, χ2=7.559, P=0.006), and patients with longer CR1 duration achieved significantly higher CR2 than those with CR1 duration less than 12 months (74.1% vs 31.9%, χ2=9.192, P=0.002). KIT D816 mutation was tightly related to shorter CR1 duration. No significant difference of 2 years post relapse survival was observed between KIT D816 mutation and non-KIT D816 mutation group.
Conclusion:KIT D816 mutation at diagnosis was an adverse factor on the salvage therapy in relapsed AML with t(8;21) translocation, significantly related to shorter CR1 duration, and can be used for prediction of salvage therapy response. KIT D816 mutation could guide the decision-making of salvage therapy in relapsed AML with t(8;21) translocation.
